However, our mutation analysis revealed no difference in BRAF, NRAS, or KIT mutation status in matched brain and extracerebral metastases of melanoma patients, indicating that hyperactivation of AKT in melanoma brain metastases does not depend on the mutation status of these genes. The gene discussed is NRAS; the disease is melanoma.